Not Yet RecruitingPhase 4

Workflow Optimization During Pulse Field Ablation for Atrial Fibrillation

Taiwan60 participantsStarted 2026-06-01

Plain-language summary

To evaluate the efficacy and safety of intravenous lidocaine in reducing diaphragmatic contraction and suppressing the cough reflex during pulsed field ablation procedures.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with paroxysmal or persistent AF and are scheduled to undergo PVI.
✓. Patients who can understand the study aims and protocol and are willing to follow the protocol for one year.

Exclusion criteria

✕. Informed consent could not be obtained
✕. Known allergy to study drug lidocaine.
✕. Presence of thrombus in the LA or LA appendage
✕. Underlying significant pulmonary disease, such as asthma or COPD needing long term maintenance therapy or documented interstitial lung disease

What they're measuring

To evaluate the efficacy and safety of intravenous lidocaine during PFA ablation for diaphragm contraction and cough suppression.

Timeframe: 400 days

Trial details

NCT IDNCT07354217

SponsorNational Taiwan University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-12-31

Contact for this trial

Chih-Chieh Yu, MD.PhD

0972652038 sweetchieh@gmail.com

View on ClinicalTrials.gov More Pulsed Field Ablation trials